These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 24361306)

  • 1. The metabotropic glutamate receptors: potential drug targets for the treatment of anxiety disorders?
    Pitsikas N
    Eur J Pharmacol; 2014 Jan; 723():181-4. PubMed ID: 24361306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabotropic glutamate receptors as targets for novel anxiolytics.
    Ferraguti F
    Curr Opin Pharmacol; 2018 Feb; 38():37-42. PubMed ID: 29494817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel metabotropic glutamate receptor 4 and glutamate receptor 8 therapeutics for the treatment of anxiety.
    Raber J; Duvoisin RM
    Expert Opin Investig Drugs; 2015 Apr; 24(4):519-28. PubMed ID: 25518990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glutamate-based anxiolytic ligands in clinical trials.
    Wierońska JM; Pilc A
    Expert Opin Investig Drugs; 2013 Aug; 22(8):1007-22. PubMed ID: 23718208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabotropic glutamatergic receptors and their ligands in drug addiction.
    Pomierny-Chamioło L; Rup K; Pomierny B; Niedzielska E; Kalivas PW; Filip M
    Pharmacol Ther; 2014 Jun; 142(3):281-305. PubMed ID: 24362085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs.
    Palucha A; Pilc A
    Pharmacol Ther; 2007 Jul; 115(1):116-47. PubMed ID: 17582504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutamate and anxiety.
    Bergink V; van Megen HJ; Westenberg HG
    Eur Neuropsychopharmacol; 2004 May; 14(3):175-83. PubMed ID: 15056476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabotropic glutamate receptors: their therapeutic potential in anxiety.
    Spooren W; Lesage A; Lavreysen H; Gasparini F; Steckler T
    Curr Top Behav Neurosci; 2010; 2():391-413. PubMed ID: 21309118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity relationships for negative allosteric mGluR5 modulators.
    Kaae BH; Harpsøe K; Kvist T; Mathiesen JM; Mølck C; Gloriam D; Jimenez HN; Uberti MA; Nielsen SM; Nielsen B; Bräuner-Osborne H; Sauerberg P; Clausen RP; Madsen U
    ChemMedChem; 2012 Mar; 7(3):440-51. PubMed ID: 22267204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New perspectives in glutamate and anxiety.
    Riaza Bermudo-Soriano C; Perez-Rodriguez MM; Vaquero-Lorenzo C; Baca-Garcia E
    Pharmacol Biochem Behav; 2012 Feb; 100(4):752-74. PubMed ID: 21569789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo characterization of MPEP, an allosteric modulator of the metabotropic glutamate receptor subtype 5: review article.
    Kuhn R; Pagano A; Stoehr N; Vranesic I; Flor PJ; Lingenhöhl K; Spooren W; Gentsch C; Vassout A; Pilc A; Gasparini F
    Amino Acids; 2002; 23(1-3):207-11. PubMed ID: 12373539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutamate receptor ligands as anxiolytics.
    Chojnacka-Wójcik E; Kłodzinska A; Pilc A
    Curr Opin Investig Drugs; 2001 Aug; 2(8):1112-9. PubMed ID: 11892923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders.
    Swanson CJ; Bures M; Johnson MP; Linden AM; Monn JA; Schoepp DD
    Nat Rev Drug Discov; 2005 Feb; 4(2):131-44. PubMed ID: 15665858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Glutamatergic neurotransmission as molecular target in anxiety].
    Carobrez Ade P
    Braz J Psychiatry; 2003 Dec; 25 Suppl 2():52-8. PubMed ID: 14978588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabotropic glutamate receptor 7: at the interface of cognition and emotion.
    O'Connor RM; Finger BC; Flor PJ; Cryan JF
    Eur J Pharmacol; 2010 Aug; 639(1-3):123-31. PubMed ID: 20371242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting metabotropic glutamate receptors for the treatment of depression and other stress-related disorders.
    Dogra S; Conn PJ
    Neuropharmacology; 2021 Sep; 196():108687. PubMed ID: 34175327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Metabotropic glutamate receptors: new molecular targets in the treatment of neurological and psychiatric diseases].
    Luján-Miras R
    Rev Neurol; 2005 Jan 1-15; 40(1):43-53. PubMed ID: 15696426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabotropic glutamate receptors as a strategic target for the treatment of epilepsy.
    Alexander GM; Godwin DW
    Epilepsy Res; 2006 Sep; 71(1):1-22. PubMed ID: 16787741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabotropic glutamate mGlu1 receptor stimulation and blockade: therapeutic opportunities in psychiatric illness.
    Lesage A; Steckler T
    Eur J Pharmacol; 2010 Aug; 639(1-3):2-16. PubMed ID: 20371230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of the brain-gut axis by group III metabotropic glutamate receptors.
    Julio-Pieper M; O'Connor RM; Dinan TG; Cryan JF
    Eur J Pharmacol; 2013 Jan; 698(1-3):19-30. PubMed ID: 23123053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.